Germfree has released bioGO. The biomanufacturing platform represents a new approach to quick and flexible production space. The company created bioGO in response to limited and rigid infrastructure options for launching biopharmaceutical projects. The Adaptive Platform delivers advanced mobile and modular bioprocess suites that provide an unprecedented level of flexibility and scalability to keep up with the rapid pace of innovation.
New bioGO Adaptive Bioproduction Platform delivers ultra-flexible modular and mobile facilities for biotech R&D and biopharmaceutical production
"The bioGO Platform represents the future of GMP compliant cleanrooms and biocontainment spaces," Kevin Kyle, President of Germfree said. "Our facilities are fully adaptable to customer requirements and process changes. bioGO Mobile can literally be rolled up for a campaign, or any short-term need, while bioGO Modular offers permanent installations that can still be repurposed and relocated. Our proprietary technology for connecting multiple bioGO units allows for maximum flexibility of size and layout. These factory-built modules provide a fast-track to a validated bioprocessing suite, normally in half the time of traditional construction."
Improving operational efficiency in early stage drug development is critical to accelerating time to market. This is particularly important for the biopharmaceutical sector, which requires 'bioproduction agility'. This means readily adapting to smaller scale production, matching 'space-to-process' and handling reconfigurations or requirements for biocontainment. Germfree's flexible platform is engineered to solve these challenges.